Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 20/20 | 0.79 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.79 |
| ▸ | HTR2A | P28223 | 2/20 | 0.79 |
| ▸ | DRD2 | P14416 | 1/20 | 0.79 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.79 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.79 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.79 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6348768 | 1.00 | CCR3 (0.79) | CCR3CYP2D6HTR2ADRD2SLC6A2 | |
| SCHEMBL6355633 | 0.94 | CCR3 (0.79) | CCR3CYP2D6HTR2ADRD2SLC6A2 | |
| SCHEMBL6355632 | 0.94 | CCR3 (0.79) | CCR3CYP2D6HTR2ADRD2SLC6A2 | |
| SCHEMBL6344473 | 0.93 | CCR3 (0.83) | CCR3CYP2D6HTR2ADRD2SLC6A2 | |
| SCHEMBL6983565 | 0.93 | CCR3 (0.83) | CCR3CYP2D6HTR2ADRD2SLC6A2 | |
| SCHEMBL6344475 | 0.93 | CCR3 (0.83) | CCR3CYP2D6HTR2ADRD2SLC6A2 | |
| SCHEMBL6354935 | 0.93 | CCR3 (0.75) | CCR3CYP2D6HTR2ADRD2SLC6A2 | |
| SCHEMBL6344677 | 0.93 | CCR3 (0.75) | CCR3CYP2D6HTR2ADRD2SLC6A2 | |
| SCHEMBL6354939 | 0.93 | CCR3 (0.75) | CCR3CYP2D6HTR2ADRD2SLC6A2 | |
| SCHEMBL6344673 | 0.93 | CCR3 (0.75) | CCR3CYP2D6HTR2ADRD2SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040058961-A1 | N-ureidoheterocycloalkyl-piperidines as modulators of chemokine receptor activity | KO SOO S (US) | 2004-03-25 | — | — | US | claimed |
| US-6627629-B2 | Useful for the treatment or prevention of asthma and other allergic diseases. | BRISTOL-MYERS SQUIBB PHARMA | 2003-09-30 | — | — | US | claimed |
| US-20030032654-A1 | N-ureidoheterocycloalkyl-piperidines as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-02-13 | — | — | US | claimed |
| US-6949546-B2 | N-ureidoheterocycloalkyl-piperidines as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-09-27 | — | — | US | disclosed |
| US-20040058961-A1 | N-ureidoheterocycloalkyl-piperidines as modulators of chemokine receptor activity | KO SOO S (US) | 2004-03-25 | — | — | US | disclosed |
| US-6627629-B2 | Useful for the treatment or prevention of asthma and other allergic diseases. | BRISTOL-MYERS SQUIBB PHARMA | 2003-09-30 | — | — | US | disclosed |
| US-20030032654-A1 | N-ureidoheterocycloalkyl-piperidines as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058961-A1 | N-ureidoheterocycloalkyl-piperidines as modulators of chemokine receptor activity | CCR3, CCR1, ACKR3 | CCR3 1/4885CYP2D6 2961/4885HTR2A 1976/4885 |
| US-20030032654-A1 | N-ureidoheterocycloalkyl-piperidines as modulators of chemokine receptor activity | CCR3, CCR1, ACKR3 | CCR3 1/4885CYP2D6 2961/4885HTR2A 1976/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.